| Literature DB >> 35203864 |
Aurora Piazza1, Matteo Perini2, Carola Mauri3, Francesco Comandatore2, Elisa Meroni3, Francesco Luzzaro3, Luigi Principe3.
Abstract
The rise of a new hypervirulent variant of Klebsiella pneumoniae (hvKp) was recently reported, mainly linked to the ST23 lineage. The hvKp variants can cause severe infections, including hepatic abscesses, bacteremia, and meningitis, with a particularly disconcerting propensity to cause community-acquired, life-threatening infection among young and otherwise healthy individuals. The present study aimed to report the clinical characteristics of a hypermucoviscous K. pneumoniae strain isolated in Italy and sustaining recurrent meningitis in a patient of Peruvian origin. A further objective was to retrospectively investigate, by means of whole-genome sequencing (WGS) analysis, the genomic features of such an isolate. The hypermucoviscosity phenotype of the strain (sk205y205t) was determined using the string test. Genomic information was obtained by WGS (Illumina) and bioinformatic analysis. Strain sk205y205t was susceptible to most antibiotics, despite the presence of some resistance genes, including blaSHV-11, blaSHV-67, fosA, and acrR. The isolate belonged to ST65 and serotype K2, and exhibited several virulence factors related to the hvKp variant. Among these, were the siderophore genes entB, irp2, iroN, iroB, and iucA; the capsule-regulating genes rmpA and rmpA2; and the type 1 and 3 fimbriae fimH27 and mrkD, respectively. A further operon, encoding the genotoxin colibactin (clbA-Q), was also identified. The virulence plasmids pK2044, pRJA166b, and pNDM. MAR were also detected. Phylogenetic investigation showed that this Italian strain is highly similar to a Chinese isolate, suggesting a hidden circulation of this hvKp ST65 K2 lineage.Entities:
Keywords: Klebsiella pneumoniae; ST65; hypermucoviscous; hypervirulent; invasive infection; meningitis; virulence determinants
Year: 2022 PMID: 35203864 PMCID: PMC8868201 DOI: 10.3390/antibiotics11020261
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Susceptibility profiles of K. pneumoniae isolated from blood, cerebrospinal fluid, and urine. Minimum inhibitory concentrations (MICs) were interpreted using EUCAST criteria.
| Isolate from Blood | Isolate from CSF a | Isolate from Urine | |
|---|---|---|---|
| Antimicrobial Agent | MIC b (Interpretation) | MIC (Interpretation) | MIC (Interpretation) |
| Amoxicillin/clavulanic acid | ≤2 (S) | ≤2 (S) | ≤2 (S) |
| Piperacillin/Tazobactam | ≤4 (S) | ≤4 (S) | ≤4 (S) |
| Cefotaxime | ≤0.25 (S) | ≤0.25 (S) | ≤0.25 (S) |
| Ceftazidime | ≤0.5 (S) | ≤0.5 (S) | ≤0.5 (S) |
| Ertapenem | ≤0.12 (S) | ≤0.12 (S) | ≤0.12 (S) |
| Meropenem | ≤0.12 (S) | ≤0.12 (S) | ≤0.12 (S) |
| Imipenem | ≤0.5 (S) | ≤0.5 (S) | ≤0.5 (S) |
| Amikacin | ≤4 (S) | ≤4 (S) | ≤4 (S) |
| Gentamycin | ≤0.5 (S) | ≤0.5 (S) | ≤0.5 (S) |
| Ciprofloxacin | ≤0.06 (S) | ≤0.06 (S) | ≤0.06 (S) |
| Ceftazidime/Avibactam | ≤0.5 (S) | ≤0.5 (S) | ≤0.5 (S) |
| Ceftolozane/Tazobactam | ≤0.5 (S) | ≤0.5 (S) | ≤0.5 (S) |
| Colistin | 0.5 (S) | 0.5 (S) | 0.5 (S) |
| Tigecycline | 0.5 (S) | 0.5 (S) | 0.5 (S) |
| Trimethoprim/Sulfametoxazole | ≤20 (S) | ≤20 (S) | ≤20 (S) |
a CSF: cerebrospinal fluid; b MIC values are in mg/L.
Virulence factors and genomic features of the sk205y205t and LC-1574/18 K. pneumoniae strains.
| Features of Virulence and Resistance | |
|---|---|
| HM phenotype | Positive |
| Capsule serotype | K2 |
| Sequence type | ST65 |
|
| |
|
| + |
|
| + |
|
| |
| Enterobactin ( | + |
| Aerobactin ( | + |
| Aerobactin receptor ( | + |
| Yersiniabactin ( | + |
| Salmochelin ( | + |
| Salmochelin receptor ( | + |
|
| |
| Type 3 fimbrial genes ( | + |
| Type 1 fimbrial genes ( | + |
|
| |
| Colibactin ( | + |
|
| |
| – | |
|
| |
| β-lactamases | |
| Aminoglycoside resistance genes | – |
| Other resistance genes |
|
| Efflux pump associated genes | |
Notes: ‘+’ indicates the presence of the corresponding gene. ‘–’ indicates the absence of the corresponding gene. Abbreviation: HM, hypermucoviscosity.
Figure 1Maximum likelihood phylogenetic tree including the sk205y205t K. pneumoniae isolate (in red and bold type) and background strains retrieved from the PATRIC database. The geographic origin of all the strains is reported on the first level colored ring. The sequence type of the strains is indicated on the second colored ring.
Clinical features related to cases of meningitis sustained by hmKp/hvKp, as extracted from the scientific literature.
| Reference | Gender, Age, | Underlying Illness | Other Risk Factors | Medical History | Other Findings | Treatment | Outcome |
|---|---|---|---|---|---|---|---|
| This work | M, 75, | No chronic illness | None | No significant medical history | Urinary tract infection, bloodstream infection | On admission: ceftriaxone and ampicillin then changed to meropenem, gentamycin and colistin. After laboratory findings and improvement of clinical conditions treatment was switched to ceftriaxone and gentamycin | Clinical improvement |
| Doud at al., 2009 [ | M, 49, | Positive IgM and IgG for Dengue fever | None | No significant medical history | Multiple liver abscess | Meropenem, subsequently changed to ceftriaxone | Clinical resolution |
| Patel et al., 2013 [ | F, 68, | HTLV-1 positive, Alzheimer’s dementia, depression | None | Cervical cancer (treated 20 years before) | Multiloculated pyogenic liver abscess | Meropenem (2 g tid for 7 days), subsequently changed to ceftriaxone (2 g bid for 2 weeks) and then to amoxicillin/clavulanate (875 mg bid for 3 weeks) | Clinical resolution |
| Alsaedi et al., 2014 [ | M, 62, | Chronic HBV infection | IgG2 deficiency | Treated pulmonary tuberculosis when he was 12, hypertension, mild chronic renal insufficiency, chronic obstructive lung disease | No foci of infection | Cefazolin (on admission) subsequently changed to ceftriaxone (>6 weeks therapy) | Clinical resolution |
| Melot et al., 2016 [ | M, 55, Guadeloupean | Hypertension | Alcoholism | Benign prostate hyperplasia, hyperlipidemia, obstructive sleep apnea | Left mastoiditis, no liver abscess | Cefotaxime | Clinical resolution |
| Iwasakiet al., | M, 72, | Hypertension, DM, cerebral hemorrhage without neurosurgical intervention, chronic pancreatitis | Alcoholism, heavy smoking (20 cigarettes daily) | 5 days before admission, he was diagnosed with otitis media and underwent myringotomy (the discharge was not cultured) | No foci of infection | On admission: ampicillin, ceftriaxone, vancomycin; therefore changed with ceftriaxone alone | Clinical resolution |
| Khaertynov et al., | M, | No illness | None | Full-term (40-week-gestation) neonate, born by cesarean delivery from a 24-year-old woman. The mother had no history of infections before delivery and no complications during pregnancy | No foci of infection | Ampicillin (200 mg/kg/day) and amikacin (10 mg/kg/day) on admission, then changed to meropenem (120 mg/kg/day) for 15 days and then to cefoperazone (100 mg/kg/day) | Cerebral edema and death |
| Maheswaranathan et al., 2018 [ | F, 61, | No chronic illness | Impaired glucose tolerance without diagnostic criteria for DM | No significant medical history | Liver abscess | On admission: meropenem and intrathecal gentamycin. Meropenem was changed to cefepime and ciprofloxacin | She developed diabetes insipidus, uncal herniation and progressed to brain death |
| Hosoda et al., 2019 [ | M, 71, | HBV and HTLV-1 | Alcoholism | No significant medical history | Liver abscess. | Meropenem | Death due to cardiopulmonary arrest |
| Shi et al., 2019 [ | M, 58, | No chronic illness | None | No significant medical history | Pulmonary abscess and bacteremia. | On admission: imipenem-cilastatin, tigecycline, voriconazole then changed to meropenem combined with 5-fluorocytosine and fluconazole | Death due to respiratory and cardiac arrest caused by cerebral hernia |
| Rodrigues et al., 2020 [ | Unknown | HIV infection, DM | Alcoholism | No recent hospital admissions | No foci of infection | Cefotaxime (2 g × 6 then increased to 3 g × 6) and ofloxacin. | Clinical resolution |
| Macleod et al., 2021 [ | F, 60, | DM | None | No significant medical history | Liver and pulmonary abscess | On admission amoxicillin/clavulanate (1.2 g tid), empirical changed to cefotaxime (2 g qid) and acyclovir (10 mg/kg tid) | Death |
| Marinakis et al., 2021 [ | F, 57, | DM untreated | None | No significant medical history | Abscess in liver segment VII and spleen | On admission: ceftriaxone, vancomycin, ampicillin/sulbactam, dexamethasone then de-escalated to ceftriaxone and subsequently changed to meropenem and tigecycline | Death in ICU due to MOF |
| M, 50, | DM untreated | Alcoholism | No significant medical history | Abscess in both lungs and liver segment VII | On admission: ceftriaxone, vancomycin, dexamethasone | Death in ICU due to cerebral oedema | |
| M, 45, | DM untreated | Drug user | Deep neck abscess sustained by | Negative for liver abscess | On admission: meropenem, vancomycin, colistin, dexamethasone | Death in ICU due to MOF | |
| Oh et al., 2021 [ | F, 57, | No chronic illness- | None | No significant medical history | Liver abscess and cholecystitis | On admission: cefotaxime (2 g × 6), vancomycin (25 mg/kg every 24 h) followed by 18 mg/kg every 12 h) + dexamethasone (10 mg qid) then changed to ciprofloxacin (400 mg bid) | Death in ICU due to MOF |
| Troché et al., 2021 [ | M, 54, Unknown | No chronic illness | None | No significant medical history | Liver abscess, multiple pulmonary nodules, endophthalmitis, hyperdense prostatic lesion and soft tissue abscess of both limbs | On admission: cefotaxime (200 mg/kg/die), acyclovir (30 mg/kg/die) then changed to ofloxacin and cefotaxime. | Clinical resolution |
Abbreviations: DM, diabetes mellitus; MOF, multiple organ failure.
Laboratory findings related to clinical cases of meningitis sustained by hmKp/hvKp.
| Reference | Gender, Age, | Resistance Profile | Antibiotic Resistance Determinants | Virulence Factors | Capsule | Sequence | Note |
|---|---|---|---|---|---|---|---|
| This work | M, 75, Peruvian | - | K2 | ST65 | String test positive | ||
| Doud et al., 2009 [ | M, 49, | Ampicillin, ampicillin/sulbactam | - | ( | K2 | - | String test positive |
| Patel et al., 2013 [ | F, 68, | - | - | - | - | String test positive | |
| Alsaedi et al., 2014 [ | M, 62, | Ampicillin, piperacillin | - | K1 | - | String test positive | |
| Melot et al., 2016 [ | M, 55, Guadeloupean | Ampicillin, piperacillin |
| K2 | ST86 | - | |
| Iwasaki et al., | M, 72, | Ampicillin, piperacillin | - | K54 | ST29 | String test positive | |
| Khaertynov et al., 2017 [ | M, | Ampicillin, amoxicillin/clavulanate, ceftazidime, cefotaxime, ceftriaxone, amikacin, gentamicin, ciprofloxacin | ESBL positive | - | - | String test positive | |
| Maheswaranathanet al., 2018 [ | F, 61, | - | - | - | - | - | String test positive |
| Hosoda et al., 2019 [ | M, 71, | - | - | K1 | ST23 | String test positive | |
| Shi et al., 2019 [ | M, 58, | Ampicillin | - | - | - | - | String test positive |
| Rodrigues et al., 2020 [ | Unknown | - | Isolate did not carry the intrinsic | K2 | ST66 | - | |
| Macleod et al., 2021 [ | F, 60s, | Ampicillin | - | K1 | Single-locus variant of ST23 | String test positive | |
| Marinakis et al., 2021 [ | F, 57, | - | - | - | - | - | - |
| M, 50, | Amoxicillin/clavulanate, cefotaxime, ceftazidime, cefepime, ceftriaxone | ESBL positive | - | - | - | - | |
| M, 45, | - | - | - | - | - | - | |
| Oh et al., 2021 [ | F, 57, | - | - | - | K1 | - | String test positive |
| Troché et al., 2021 [ | M, 54, Unknown | - | - | - | - | - | String test positive |